Radiopharmaceuticals in sentinel lymph-node detection – an overview

Wilhelm, Abraham J.; Mijnhout, G. Sophie; Franssen, Ejf

doi:10.1007/pl00014793

Cited by 200 publications

(103 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The oldest application of nanoradiopharmaceuticals (actually developed in the sixties [18], i.e., years ago before the word "nano" became so popular) is radiodiagnostic imaging of reticuloendothelial system (RES), especially of liver, spleen and sentinel lymph nodes [18][19][20][21] of the parts of body impaired by malignancies, by planar scintigraphy or single photon emission computed tomography (SPECT). The main principle is that nanoparticles with surface recognized by the body as foreign rapidly accumulate in RES to be destroyed and eliminated from the body.…”

Section: Imaging Of Reticuloendothelial System With Radiolabeled Nanomentioning

confidence: 99%

“…The radionuclide 99mj c (T· = 6.01 h) cheaply available from the "Mo-"Tc generator has optimal γ-photon energy for imaging (140.5 keV, 89%) and is the far most widespreadly used radionuclide for planar scintigraphy and SPECT. The 99m Tc-sulfur colloid is produced by acidification of thiosulfate and technetium is bound to them due to its affinity to soft Lewis bases such as sulfide (i.e., it is a mixture of technetium sulfides and sulfur) [20,21]. Biodistribution may be varied by size of the particles [23].…”

Section: Imaging Of Reticuloendothelial System With Radiolabeled Nanomentioning

confidence: 99%

“…The smallest fraction of sulfur colloid (around 100 nm, usually produced by filtration of the colloid through a 0.22 micron filter) is used for lymph node imaging [20,21]. This application is currently of increasing interest [19,24], since it is able to reveal lymph nodes affected by metastatic cells from the primary cancer site (i.e.…”

Section: Imaging Of Reticuloendothelial System With Radiolabeled Nanomentioning

confidence: 99%

“…Several 99m Tc-labeled alternatives have been proposed for this purpose, such as phytate nanoparticles [25][26][27], tin colloid [19] or Sb 2 S 3 nanoparticles [21,24]. However, none of these nanoparticles became as popular as sulfur colloid.…”

Section: Imaging Of Reticuloendothelial System With Radiolabeled Nanomentioning

confidence: 99%

See 3 more Smart Citations

Nano‐sized Carrier Systems as New Materials for Nuclear Medicine

Hrubý

2012

Intelligent Nanomaterials

View full text Add to dashboard Cite

Materials with nano-sized architecture currenly attract a lot of attention for various applications because they possess many unique properties. Several of the currently most studied applications of nanotechnology are in medicine, especially in the delivery of chemical drugs, and also in nuclear medicine, which is the focus of this review. The main areas of interest for nano-sized systems exploitable in nuclear medicine are imaging of reticuloendothelial system by single photon emission tomography, radiosynovectomy with beta-emitter-labeled particles, and diagnostic or therapeutic cancer applications exploiting passive targeting of radionuclides to solid tumors by enhanced permeation and retention (EPR) effect, or by active targeting approaches.

show abstract

Section: Imaging Of Reticuloendothelial System With Radiolabeled Nanomentioning

confidence: 99%

Section: Imaging Of Reticuloendothelial System With Radiolabeled Nanomentioning

confidence: 99%

Section: Imaging Of Reticuloendothelial System With Radiolabeled Nanomentioning

confidence: 99%

Section: Imaging Of Reticuloendothelial System With Radiolabeled Nanomentioning

confidence: 99%

See 2 more Smart Citations

Nano‐sized Carrier Systems as New Materials for Nuclear Medicine

Hrubý

2012

Intelligent Nanomaterials

View full text Add to dashboard Cite

show abstract

“…Die Ver wen dung eines ge fil ter ten Tra cers mit mög lichst kleiner Va ri anz der Par ti kel grö ße ver bes sert die Vor her sag bar keit des zeit ab hän gi gen Ef fekts. Mit ab neh men der Par ti kel grö ße steigt die Mi gra ti ons ge schwin dig keit nach In jek ti on [25]. Im Tier mo dell zei gen sich zu dem bes se re De tek ti ons ra ten bei Verwen dung ge fil ter ter Tra cer [24].…”

Section: Prä Ope Ra Ti Ves Vor Ge Henunclassified

Techniken zur Markierung des Sentinellymphknotens beim Mammakarzinom

et al. 2005

View full text Add to dashboard Cite

nas · D. Die sing · K. Died rich · M. Fried rich Kli nik für Gy nä ko lo gie und Ge burts hil fe, Uni ver si täts kli ni kum Schles wig-Hol stein, Cam pus Lü beck Tech ni ken zur Mar kie rung des Sen ti nellymph kno tens beim Mam ma kar zi nom Gynäkologe 2005 · 38:877-884 On li ne pub li ziert: 7. Ok to ber 2005 © Sprin ger Me di zin Ver lag 2005Nach Di ag no se stel lung ei nes Mammakar zi noms ist die Er he bung des axil lä ren Lymph kno ten sta tus durch die kon ven tionel le axil lä re Lym pho no dek to mie des Level I und II mit der Ent fer nung von mindes tens 10 Lymph kno ten wei ter hin der ope ra ti ve Gold stan dard. Sie dient der histo pa tho lo gi schen Tu mor klas si fi ka ti on, der Pro gno seab schät zung und der lo kore gio nären Tu mor kon trol le. Das Er gebnis trägt auch zur ad ju van ten The ra pieent schei dung bei. Bei der kon ven tio nell durch ge führ ten Axil la dis sek ti on kann es al ler dings zu Kom pli ka tio nen im Drai nage-und Ope ra ti ons ge biet mit kon se kutiv er höh ter Mor bi di tät kom men. Häu fig sind Schmer zen bei Arm be we gung und Ein schrän kun gen der Arm be weg lich keit, Taub heit im Schnitt füh rungs be reich und ein Lym ph ödem des be trof fe nen Arms. Auch be we gungs u n ab hän gi ge Be schwerden kom men vor.Das Sen ti nel ver fah ren ("sen ti nel lymph node bi o psy") ist als mi ni mal-inva si ves Ver fah ren eine Al ter na ti ve zur axil lä ren Lym pho no dek to mie. Bei tu morfrei em Sen ti nellymph kno ten ist die periund post ope ra ti ve Mor bi di tät sig ni fi kant ver min dert. Auf die Durch füh rung ei ner kon ven tio nel len axil lä ren Lym pho no dekto mie kann aber nur dann ver zich tet werden, wenn in den Sen ti nellymph kno ten sowohl in der in tra ope ra ti ven Schnell schnittdia gno s tik als auch in der end gül ti gen histo pa tho lo gi schen Un ter su chung kei ne me ta sta ti sche In fil tra ti on durch das Mamma kar zi nom nach ge wie sen wird. Die Senti nellymph kno ten bi op sie dient -wie die axil lä re Lym pho no dek to mie -dem Staging und der Tu mor kon trol le bei his to logisch ge si cher tem Mam ma kar zi nom und trägt zum The ra pie ent scheid in der Ad juvanz bei. Prin zip des Sen ti nel ver fah rensDer Sen ti nellymph kno ten ist der ers te Lymph kno ten im lym pha ti schen Drai na gege biet des Mamm akar zi noms (. Abb. 1). Die axil lä ren Lymph kno ten der Le vel I-II (sel te ner Le vel III), Lymph kno ten im Ver lauf der A. mam ma ria in ter na (IMA, <5), (sel ten) su pra kla vi ku lä re Lymphkno ten und auch in tra mam mä re Lymphkno ten sind für den Lym ph ab fluss der Brust ver ant wort lich. Die Wahr schein lichkeit ei nes me ta sta ti schen Be falls durch Zellen des Mamm akar zi noms im Lym ph system ist hier am höchs ten. Es kön nen auch meh re re Lymph kno ten als Sen ti nellymphkno ten fun gie ren, da gleich zei tig meh rere Lymph ge fä ße Tu mor zel len ei nes Tumor ge bie tes in un ter schied li che Lymphkno ten trans por tie ren kön nen. Die Lage des Tu mors kann prä dis po nie rend für die Lymph kno ten sta ti o...

show abstract

Sentinel lymph node biopsy as an alternative to routine axillary lymph node dissection in breast cancer patients

Noguchi

2001

J. Surg. Oncol.

View full text Add to dashboard Cite

Sentinel lymph node (SLN) biopsy is a useful way of assessing axillary nodal status and obviating axillary lymph node dissection (ALND) in patients with node-negative breast cancer. Because SLN technology is evolving rapidly, however, variation in technique is widespread, and no standardization has yet been accomplished. This review discusses the feasibility and accuracy of this procedure and suggests the optimal method for identifying the SLN and detecting micrometastases. Although the SLN can be successfully identified by either the dye-guided or gamma probe-guided method in experienced hands, identification is facilitated when the two techniques are used together. In the gamma probe-guided method, the use of a large-sized radiotracer (particle size, 200-1000 nm) may be preferred because only one or two SLNs are identified. To increase the chance of finding metastases in SLN, it is desirable to make step sections with hematoxylin and eosin staining on permanent and frozen sections. The addition of immunohistochemistry may improve the accuracy of SLN diagnosis. The intraoperative examination of imprint cytology may be useful in determining the status of the SLNs, but further studies are needed to establish whether it has additional value when combined with the frozen section. In practice, routine ALND can be avoided when there is documentation of extensive experience and a low false-negative rate with the technique in the hands of a particular surgeon and hospital team. Particularly, SLN biopsy is more successful and has a lower false-negative rate in patients with smaller tumors. However, investigation of long-term regional control and survival in a prospective randomized trial is necessary, before SLN biopsy can replace routine ALND as the preferred staging operation for women with breast cancer.

show abstract

Radiopharmaceuticals in sentinel lymph-node detection – an overview

Cited by 200 publications

References 22 publications

Nano‐sized Carrier Systems as New Materials for Nuclear Medicine

Nano‐sized Carrier Systems as New Materials for Nuclear Medicine

Techniken zur Markierung des Sentinellymphknotens beim Mammakarzinom

Sentinel lymph node biopsy as an alternative to routine axillary lymph node dissection in breast cancer patients

Contact Info

Product

Resources

About